Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
By Kunal DasAtavistik Bio said on Thursday it has signed a deal with Swiss drugmaker Roche BX:RHO potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases.Here are some details
Drug developer Atavistik Bio said on Thursday it has signed a deal with Swiss drugmaker Roche BX:RHO potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases.Here are some details